综述
ENGLISH ABSTRACT
狼疮抗凝物检测在静脉血栓栓塞症中的应用进展
胡长春
王晓慧
陈虹
作者及单位信息
·
DOI: 10.3760/cma.j.cn112147-20210519-00339
Progress of lupus anticoagulant detection in venous thromboembolism
Hu Changchun
Wang Xiaohui
Chen Hong
Authors Info & Affiliations
Hu Changchun
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Wang Xiaohui
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Chen Hong
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
·
DOI: 10.3760/cma.j.cn112147-20210519-00339
1321
251
0
0
13
3
PDF下载
APP内阅读
摘要

狼疮抗凝物是发生静脉血栓栓塞症的危险因素之一,在静脉血栓栓塞症患者中检测狼疮抗凝物,对治疗方案抉择和疗效预后判断等方面具有重要意义。目前尚无相关文献对狼疮抗凝物检测在静脉血栓栓塞症中的应用进展进行分析总结,为加深对此类患者的认识,更好地帮助临床医生对此类患者进行合理的诊治和管理,现就有关流行病学、检测注意事项及检测结果在静脉血栓栓塞症中的价值和相关治疗进行综述。

ABSTRACT

Lupus anticoagulant is one of the risk factors for venous thromboembolism, and the detection of lupus anticoagulant in patients with venous thromboembolism is important for the choice of treatment options and prognosis of treatment. There was no relevant literature to analyze and summarize the application progress of lupus anticoagulant detection in venous thromboembolism. In order to deepen the understanding of such patients, and help clinicians to conduct reasonable diagnosis, treatment and management of these patients, we reviewed the relevant epidemiology, test precautions, and the value of test results in venous thromboembolism and related treatments.

Chen Hong, Email: mocdef.6ab213002gnohepoh
引用本文

胡长春,王晓慧,陈虹. 狼疮抗凝物检测在静脉血栓栓塞症中的应用进展[J]. 中华结核和呼吸杂志,2022,45(02):218-221.

DOI:10.3760/cma.j.cn112147-20210519-00339

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
本文评分
5 [累计1个]
静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺血栓栓塞症(PTE),两者易患因素相同,是VTE在不同部位、不同阶段的两种临床表现形式 1。狼疮抗凝物(LA)是抗磷脂抗体(aPL)家族成员之一,是一组不同种类的免疫球蛋白,在体外抑制磷脂依赖的凝血反应,产生抗凝效应,而在体内却干扰凝血酶原活性,促进血栓形成 2 , 3。LA是VTE形成的危险因素之一,在手术患者VTE风险评估表(Caprini评分表)中,LA阳性高达3分,仅此项即可使患者术后VTE发生风险达到高危(3~4分)。在临床中检测LA具有重要的价值,既能预测某些特定人群VTE的发生,又可以指导患者的治疗及预后情况,使治疗更加规范合理。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018,98(14):1060-1087. DOI: 10.3760/cma.j.issn.0376-2491.2018.14.007 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Hoxha A , Banzato A , Ruffatti A ,et al. Detection of lupus anticoagulant in the era of direct oral anticoagulants[J]. Autoimmun Rev, 2017,16(2):173-178. DOI: 10.1016/j.autrev.2016.12.010 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
邵钫钰,冯娟,王宪. 抗磷脂抗体引起血管内皮细胞功能紊乱的机制及其病理生理意义[J]. 生理科学进展, 2018,49(3):172-176. DOI: 10.3969/j.issn.0559-7765.2018.03.003 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
de Groot PG , Lutters B , Derksen RH ,et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis[J]. J Thromb Haemost, 2005,3(9): 199 3 -1997. DOI: 10.1111/j.1538-7836.2005.01485.x .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Reynaud Q , Lega JC , Mismetti P ,et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis[J]. Autoimmun Rev, 2014,13(6):595-608. DOI: 10.1016/j.autrev.2013.11.004 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
贺颖,郑红,游文凤. 40例深静脉血栓形成患者血浆LA水平的测定[J]. 河南职工医学院学报, 2003,15(1):4-5. DOI: 10.3969/j.issn.1008-9276.2003.01.002 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
马睿,任静,张珠博,. 狼疮抗凝物阳性患者临床数据横断面研究[J]. 临床检验杂志, 2020,38(7):503-507. DOI: 10.13602/j.cnki.jcls.2020.07.06 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Garcia D , Akl EA , Carr R ,et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review[J]. Blood, 2013,122(5):817-824. DOI: 10.1182/blood-2013-04-496257 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Lyle CA , Gibson E , Lovejoy AE ,et al. Acute prognostic factors for post-thrombotic syndrome in children with limb DVT: a bi-instit utional cohort study [J]. Thromb Res, 2013,131(1):37-41. DOI: 10.1016/j.thromres.2012.10.012 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Tektonidou MG , Andreoli L , Limper M ,et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019,78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Pengo V , Tripodi A , Reber G ,et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haem ost , 2009,7(10):1737-1740. DOI: 10.1111/j.1538-7836.2009.03555.x .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Pengo V , Bison E , Banzato A ,et al. Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT)[J]. Methods Mol Biol, 2017,1646:169-176. DOI: 10.1007/978-1-4939-7196-1_14 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Tripodi A , Cohen H , Devreese K . Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost, 2020,18(7):1569-1575. DOI: 10.1111/jth.14846 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Limper M , de Leeuw K , Lely AT ,et al. Diagnosing and treating antiphospholipid syndrome: a consensus paper[J]. Neth J Med, 2019,77(3):98-108.
返回引文位置Google Scholar
百度学术
万方数据
[15]
Garcia D , Erkan D . Diagnosis and Management of the Antiphospholipid Syndrome[J]. N Engl J Med, 2018,378(21):2010-2021. DOI: 10.1056/NEJMra1705454 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Stojanovich L , Djokovic A , Kontic M . Antiphospholipid-mediated thrombosis: interplay between type of antibodies and localisation of lung, and cardiovascular incidences in primary antiphospholipid syndrome[J]. Clin Exp Rheumatol, 2015,33(4):531-536.
返回引文位置Google Scholar
百度学术
万方数据
[17]
Stojanovich L , Kontic M , Djokovic A ,et al. Pulmonary events in antiphospholipid syndrome: influence of antiphospholipid antibody type and levels[J]. Scand J Rheumatol, 2012,41(3):223-226. DOI: 10.3109/03009742.2011.641580 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
王倩,钟益芳,周颖. 狼疮抗凝物质与非小细胞肺癌患者血液高凝状态及病情的关系[J]. 浙江医学, 2017,39(3):185-188.
返回引文位置Google Scholar
百度学术
万方数据
[19]
朱杰,马雅英,孙红,. 狼疮抗凝物质对大肠癌患者血液高凝状态的影响[J]. 医学研究杂志, 2014,43(12):131-133.
返回引文位置Google Scholar
百度学术
万方数据
[20]
何尚运. 肺癌患者抗凝血酶Ⅲ和狼疮抗凝物联检的临床价值[J]. 放射免疫学杂志, 2013,26(3):381-382. DOI: 10.3969/j.issn.1008-9810.2013.03.076 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
de Meis E , Monteiro RQ , Levy RA . Lung adenocarcinoma and antiphospholipid antibodies[J]. Autoimmun Rev, 2009,8(6):529-532. DOI: 10.1016/j.autrev.2009.01.010 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
宋红宝,张少华. 磷脂抗体综合征狼疮抗 凝物和血栓的临床相关性分析 [J]. 中国医药指南, 2018,16(13):112-113.
返回引文位置Google Scholar
百度学术
万方数据
[23]
陈新光,赵永强. 磷脂抗体综合征狼疮抗凝物和血栓临床相关性分析[J]. 哈尔滨医科大学学报, 2013,47(4):370-373. DOI: 10.3969/j.issn.1000-1905.2013.04.022 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
王明山,潘景业,王霄霞,. 狼疮样抗凝物质对肺血栓栓塞症的影响[J]. 中华结核和呼吸杂志, 2004,27(11):740-742. DOI: 10.3760/j:issn:1001-0939.2004.11.007 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Rosborough TK , Shepherd MF . Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant[J]. Pharmacotherapy, 2004,24(7):838-842. DOI: 10.1592/phco.24.9.838.36102 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Crowl A , Schullo-Feulner A , Moon JY . Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant[J]. Ann Pharmacother, 2014,48(11):1479-1483. DOI: 10.1177/1060028014546361 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Baquero-Salamanca M , Téllez-Arévalo AM , Calderon-Ospina C . Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?[J]. BMJ Case Rep, 2015,2015:bcr2014209013. DOI: 10.1136/bcr-2014-209013 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Crowther MA , Ginsberg JS , Julian J ,et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome[J]. N Engl J Med, 2003,349(12):1133-1138. DOI: 10.1056/NEJMoa035241 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Kearon C , Akl EA , Ornelas J ,et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report[J]. Chest, 2016,149(2):315-352. DOI: 10.1016/j.chest.2015.11.026 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Kajy M , Mathew A , Ramappa P . Treatment Failures of Direct Oral Anticoagulants[J]. Am J Ther, 2021,28(1):e87-e95. DOI: 10.1097/MJT.0000000000001083 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Pengo V , Denas G , Zoppellaro G ,et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome[J]. Blood, 2018,132(13):1365-1371. DOI: 10.1182/blood-2018-04-848333 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Ordi-Ros J , Sáez-Comet L , Pérez-Conesa M ,et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial[J]. Ann Intern Med, 2019,171(10):685-694. DOI: 10.7326/M19-0291 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Cohen H , Hunt BJ , Efthymiou M ,et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial[J]. Lancet Haematol, 2016,3(9):e426-436. DOI: 10.1016/S2352-3026(16)30079-5 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Okamura G , Kawano H , Yoshida N ,et al. Successful treatment with rivaroxaban for an acute pulmonary thromboembolism in a patient with primary antiphospholipid antibody syndrome[J]. J Cardiol Cases, 2020,21(2):79-81. DOI: 10.1016/j.jccase.2019.10.004 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Malec K , Góralczyk T , Undas A . The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome[J]. Thromb Res, 2017,152:93-97. DOI: 10.1016/j.thromres.2016.12.009 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
陈虹,Email: mocdef.6ab213002gnohepoh
B

胡长春, 王晓慧, 陈虹. 狼疮抗凝物检测在静脉血栓栓塞症中的应用进展[J]. 中华结核和呼吸杂志, 2022, 45(2): 218-221. DOI: 10.3760/cma.j.cn112147-20210519-00339.

C
所有作者声明无利益冲突
D
重庆市卫计委卫生适宜技术 (2018jstg012,2019jstg023)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号